---
title: "CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296129143.md"
description: "Revenue and net profit soared year-over-year, driven by biopharma licensing and product launches. Biopharma now dominates revenue, supported by major deals with AstraZeneca and robust R&D investment. Risks include high R&D costs, competition, and regulatory changes.Original document: CSPC Innovation Pharmaceutical Co., Ltd. Class A [300765] Interim report — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T16:04:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296129143.md)
  - [en](https://longbridge.com/en/news/296129143.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296129143.md)
generator: "portal-rs"
---

# CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth

Revenue and net profit soared year-over-year, driven by biopharma licensing and product launches. Biopharma now dominates revenue, supported by major deals with AstraZeneca and robust R&D investment. Risks include high R&D costs, competition, and regulatory changes.

Original document: CSPC Innovation Pharmaceutical Co., Ltd. Class A \[300765\] Interim report — Aug. 17 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial](https://longbridge.com/en/news/297995811.md)
- [Key facts: LSE:AZN Zegfrovy buy; SANOVO PFS; Wan Ling Martello named](https://longbridge.com/en/news/297611733.md)
- [REG - AstraZeneca PLC - Admission of Further Securities to Trading](https://longbridge.com/en/news/297665664.md)
- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**